Drugs / Plasma rich fibrin
Plasma rich fibrin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05966987 | Aug 2023 → Feb 2024 | — | Al-Azhar University | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06790758 | Jan → Nov 2025 | headache disorder | Tanta University | Completed | No outcome recorded |
| — | NCT06790745 | Jan → Oct 2025 | headache disorder | Tanta University | Completed | No outcome recorded |
| — | NCT06347640 | Apr 2023 → Dec 2025 overdue | dental pulp disorder | King Abdullah University Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | plasma-rich fibrin | “plasma-rich fibrin (PRF) derived from autologous whole blood” NCT06790745 ↗ |
| Known as | Injectable Plasma-rich Fibrin | “Injectable Plasma-rich Fibrin versus Low-Level Laser Therapy” NCT05966987 ↗ |
| Known as | PRF | “Plasma-rich fibrin (PRF) is derived from autologous whole blood” NCT06790758 ↗1“plasma-rich fibrin (PRF) derived from autologous whole blood” NCT06790745 ↗ |
| Route | Other | “Patients will receive plasma-rich fibrin epidural injection by Racz catheter” NCT06790745 ↗ |